A new pentacyclic guanidine alkaloid, monanchomycalin C (1), along with the earlier known ptilomycalin A (2), were isolated from the Far-Eastern marine sponge Monanchora pulchra. The structure of 1 was elucidated using 1D and 2D NMR spectroscopic and mass spectrometric data. Compounds 1 and 2 exhibited cytotoxic activities against human breast cancer MDA-MB-231 cells with IC 50 values of 8.2 µM and 4.3 µM, respectively.
Guanidine alkaloids from sponges of the genus Monanchora represent compounds with diverse chemical structures and biological activities [1] [2] [3] [4] [5] [6] . This group consists of bicyclic [7] [8] , tricyclic [9] [10] [11] [12] [13] [14] [15] [16] [17] , pentacyclic [8, 10, 12, [16] [17] [18] [19] [20] [21] [22] [23] [24] and acyclic [25, 26] natural products found in different species of the genus. The alkaloids demonstrate a broad spectrum of biological activities [1] [2] [3] [4] [5] [6] [7] [8] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [22] [23] [24] [25] [26] , including potent cytotoxic effects, induction of cellular apoptosis, and inhibition of the TRPV1 receptor [25, 26] .
In our laboratory, we have previously isolated seven new pentacyclic guanidine alkaloids, monanchocidins A-E [18, 19] and monanchomycalins A and B [20] from different collections of the Far-Eastern marine sponge M. pulchra.
In continuation of our search for bioactive natural products from M. pulchra, herein we report the isolation of two alkaloids. The first was established to be a new polycyclic guanidine alkaloid, monanchomycalin C (1), and the second was proved to be the previously known ptilomycalin A (2) . Ptilomycalin A has been isolated earlier from marine sponges such as Ptilocaulis spiculifer, Hemimycale sp. [27, 28] , M. arbuscula [12] , M. unguifera [17] , as well as from two starfish, namely Celerina hefferenani and Formia monilis [29] , but not from M. pulchra.
The EtOH extract of the frozen sponge was concentrated and partitioned between H 2 O and n-BuOH. The n-BuOH-soluble materials were further partitioned between n-hexane and aqueous EtOH, and the latter fraction further separated by size-exclusion chromatography on Sephadex LH-20 to obtain a crude mixture of alkaloids. Separation and purification of these was carried out by repeated HPLC to provide pure monanchomycalin C (1) and ptilomycalin A (2) [27] (0.03%, and 0.25%, respectively, based on the dry weight of the sponge). Ptilomycalin A was structurally identified by comparison of its NMR spectra with those reported in the literature [27, 28] .
The molecular formula of monanchomycalin C (1) , like the MS of monanchomycalins A and B [20] , and some two-headed sphingolipids [30] .
The NMR data of 1 in CD 3 OD ( Interpretation of the COSY, HSQC and HMBC data established that the left-hand half of the 'vessel' part of the pentacyclic core of 1 was identical to that of compounds previously found in some tropical sponges [8, 10, 16, 21, 23, 27, 28, [31] [32] [33] and starfish [29] , as well as in monanchocidins B and С from the Far-Eastern marine sponge M. pulchra [19] . However, the right-hand half contained a 2-propyltetrahydro-2H-pyran fragment ( Figure 1 a triplet signal of a methyl group at δ H 0.87 (Table 1) instead of the doublets for the C-20 methyl group (δ H 1.09-1.13) in the spectra of other related compounds [18, 19] was observed in the spectrum of compound 1. Further analysis of the 1 H and 13 C NMR data of 1 established the presence of a spermidine residue (Figure 1 ), also found in ptilomycalin A [27, 28] , celeromycalin [29] and monanchomycalins A, B [20] . Additional analysis of the 1D and 2D NMR (Table 1, Figure 1 ) and MS data showed that the "vessel" part and "anchor" part connected to each other via an unbranched polymethylene chain, representing a derivative of a C16 ω-hydroxy fatty acid. We observed that the 1 H and 13 C signals of the "anchor" moiety of monanchomycalin C (1) are accompanied by small additional signals. This peculiarity is conditioned by rotational isomerism around the amide C(38)-N linkage. Previously we reported this phenomenon for monanchomycalins A and B [20] . Similar observations were also reported by Kashman et al. [27, 28] for the ptilomycalin A per-trifluoroacetyl derivative and by Berlinck and coworkers [33] for the crambescidin 816 per-acetyl derivative. Comparison of the 1 H and 13 C NMR data of monanchomycalin С (1) for the left-hand half of the "vessel" part with those of monanchocidins B, C [19] and for the right-hand half of the "vessel" part with those of monanchomycalin A [20] suggested the same relative configuration for all the chiral carbon atoms in these compounds. Thus, the following configuration: 3R*, 8R* in the lefthand side and 15S*, 19S* in the right-hand side of the pentacyclic core are proposed.
Based on these data it can be concluded that monanchomycalin C (1) is a structural analogue of guanidine pentacyclic alkaloids from the tropical marine sponges [8, 10, 16, 21, 23, 27, 28, [31] [32] [33] , which presents a new homologue of ptilomycalin A (2), having a n-propyl group attached to C-19.
Isolation of monanchomycalin C (1) with an unprecedented combination of fragments, namely a seven-membered cycle on the left-hand half of the 'vessel' part, and of a n-propyl group at C-19, has allowed supplementation of the scheme for hypothetical pathways of pentacyclic guanidine alkaloids biogenesis, previously proposed by us [20] . Now, it is clear that both types of pentacyclic cores (with the five-membered [18] [19] [20] and seven-membered rings on the left side [19, 21, 23, 24, [27] [28] [29] 31] ) can be formed from precursors of the polyketide-type containing either 9 acetate and one propionate units (all earlier known pentacyclic guanidine alkaloids except monanchomycalins A [20] and C (1)), or 10 acetate and one propionate units, as in monanchomycalins A [20] and C (1).
The cytotoxic activity of the new compound (1) and the known ptilomycalin A (2) against human breast cancer MDA-MB-231 cells was examined using the MTS test [34] . After 48 h of treatment these alkaloids exhibited IC 50 values of 8.2 µM and 4.3 µM respectively, and, therefore, were more active than cisplatin (IC 50 = 23.0 µM) used in this assay as a reference substance.
Experimental
General: Optical rotations were measured using a Perkin-Elmer 343 polarimeter. The 1 H and 13 C NMR spectra were recorded on Bruker DRX-500 and Avance III-700 spectrometers at 500, 700, and 125, and 175 MHz, respectively, with Me 4 Si as an internal standard. ESI mass spectra (including HR ESI-MS) were obtained on an Agilent 6510 Q-TOF LC-MS spectrometer by direct injection in MeOH. Low-pressure column liquid chromatography was performed using Sephadex LH-20 (Sigma Chemical Co.). Si gel plates (4.5×6.0 cm, 5-17 µm, Sorbfil) were used for TLC and compounds were visualized by spraying with 10% H 2 SO 4 solution, followed by heating. HPLC was performed using an Agilent Series 1100 Instrument equipped with the differential refractometer RID-DE14901810 and a YMC-ODS-A (250×10 mm) column. The Cell 
Cytotoxicity assay (MTS-test):
The effect of the compounds on cell viability was evaluated using the MTS test, which is based on the reduction of MTS into its formazan product by living cells [34] . The experiment was performed as previously described [35, 36] , with slight modifications. Briefly, cells were cultured for 12 h in 96-well plates (6 × 10 3 cells per well), 100 μL/well. The medium was then replaced with fresh medium containing substances at various concentrations in a total volume of 100 μL/well and the cells were incubated for 48 h. Subsequently, 20 μL of Cell Titer 96 Aqueous One Solution Reagent was added to each well, and MTS reduction was measured spectrophotometrically 2 h later at 492 and 690 nm as background using Quant equipment (Bio-Tek Instruments, Winooski, VT, USA). Results are represented as IC 50 values (inhibition concentration 50%) of the substances. Cisplatin (cisdiamminedichloroplatinum (II), 1 mg/mL in dH 2 O, NeoCorp, Weilheim, Germany) was used as a reference substance.
